Table. 3.

Serum HBV Markers Analysis from Mouse Model of HBV Infection Involving HBV Recombinant (r) cccDNA.

Treatmenta	HBV DNA (log10 ± SD)			HBsAg (%)
	Day 20b	Day 20 – Baselinec	Change from vehicled	Day 20/Baselinee	Ratio to vehiclef
Vehicle	4.78 ± 0.57	−0.70 ± 0.54	n.s.	86.41 ± 8.68	n.s.
ETV(0.02 mg/kg)	2.93 ± 0.73	−2.46 ± 0.90	−1.85 ± 0.73**	82.78 ± 11.07	95.80 ± 12.82
6-AN(5 mg/kg)	3.47 ± 0.84	−2.10 ± 0.91	−1.31 ± 0.84*	45.12 ± 13.26	52.22 ± 15.35**
6-AN+ETV	2.51 ± 0.61	−3.03 ± 0.63	−2.27 ± 0.61**	39.11 ± 9.71	45.26 ± 11.23**

At day 20, the levels of serum HBV DNA and the ratio of HBsAg from mouse model of HBV infection involving HBV recombinant (r) cccDNA were shown in Table 3 (n = 6 per group). (* P < 0.05, ^⁎⁎p < 0.01, n.s., not significant, compared with the vehicle group).

6-AN, 6-Aminonicotinamide; HBsAg, Hepatitis B surface antigen; ETV, Entecavir.

^aTreatment doses and schedules as described in the Methods section.

^bMean log₁₀ values ± standard error (copies/ml).

^cMean log₁₀ change values ± standard error (copies/ml) from baseline.

^dMean log₁₀ change values ± standard error (copies/ml) from vehicle.

^eMean ratio values ± standard error of HBsAg to baseline.

^fMean ratio values ± standard error of HBsAg to vehicle.